Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tet1tm1.2Jae mutation
(0 available);
any
Tet1 mutation
(142 available)
Tet2tm1.1Iaai mutation
(2 available);
any
Tet2 mutation
(778 available)
Tet3tm1.1Yzhg mutation
(0 available);
any
Tet3 mutation
(59 available)
Tg(Rorc-cre)1Litt mutation
(1 available)
|
|
|
growth/size/body
|
|
• splenomegaly at age 5 weeks
|
hematopoietic system
|
|
• splenomegaly at age 5 weeks
|
immune system
|
|
• splenomegaly at age 5 weeks
|
|
|
• lymphadenopathy at age 5 weeks
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tet1tm1.2Jae mutation
(0 available);
any
Tet1 mutation
(142 available)
Tet2tm1.1Iaai mutation
(2 available);
any
Tet2 mutation
(778 available)
Tet3tm1.1Yzhg mutation
(0 available);
any
Tet3 mutation
(59 available)
Tg(Rorc-cre)1Litt mutation
(1 available)
|
|
|
hematopoietic system
|
|
• greatly reduced CD4 expression upon T cell proliferation
|
immune system
|
N |
• no autoimmune phenotypes
• normal spleen and lymph node size
• normal proportions of naive CD44- CD62L+ T lymphocyte compartments
|
|
|
• greatly reduced CD4 expression upon T cell proliferation
|
hematopoietic system
|
|
• block in erythroblast development results in an increase in cells at development stage R2 and a decrease in R4 population in spleen by 12 weeks post-piPC
|
|
|
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with pIPC results in increasing (46.5% to 90%) donor chimerism beginning at 16 weeks post transplantation as compared to mice carrying only the Sf3b1tm1.1Mdf allele and wild-type
|
|
|
• progressive macrocytic anemia 45 weeks post pIPC treatment
|
|
|
• spleens contain dysplastic megakaryocytes 45 weeks post-piPC treatment
|
|
|
• spleens contain dysplastic erythroid progenitors 45 weeks post-piPC treatment
|
|
|
• observed at 45 weeks post-pIPC injection
• phenotype is increased in severity as compared to mice carrying only the Sf3b1tm1.1Mdf allele
|
|
|
• increased percentage of granulocytes in peripheral blood and bone marrow at 45 weeks post-pIPC
|
|
|
• decrease in percentage of B cells in the spleen and bone marrow 45 weeks post-pIPC
|
|
|
• increase in long term repopulating hematopoietic stem cells (LT-HSC) at 12 and 45 weeks as compared to wild-type
• increase in multi-potent progenitors (MPP) in bone marrow 12 weeks post-piPC treatment
|
immune system
|
|
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with pIPC results in increasing (46.5% to 90%) donor chimerism beginning at 16 weeks post transplantation as compared to mice carrying only the Sf3b1tm1.1Mdf allele and wild-type
|
|
|
• increased percentage of granulocytes in peripheral blood and bone marrow at 45 weeks post-pIPC
|
|
|
• decrease in percentage of B cells in the spleen and bone marrow 45 weeks post-pIPC
|
growth/size/body
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ncstntm1.1Akli mutation
(0 available);
any
Ncstn mutation
(33 available)
Tet2tm1.1Iaai mutation
(2 available);
any
Tet2 mutation
(778 available)
Tg(VAV1-cre)1Graf mutation
(1 available)
|
|
|
mortality/aging
immune system
|
|
• with massive infiltration of differentiated and blast-like myeloid cells
|
|
|
• increased circulating blast-like cells at 7 weeks after birth
• massive infiltration of differentiated and blast-like myeloid cells in the spleen
|
|
|
• with an increase in absolute myelomonocytic and blast-like cells 7 weeks after birth
|
neoplasm
|
|
• spleen tumor cells transplanted into lethally irradiated recipients induce increased myeloid cell counts in peripheral blood and lethality compared with cells from control mice
|
|
|
• massive infiltration of differentiated and blast-like myeloid cells in the spleen
|
hematopoietic system
|
|
• with massive infiltration of differentiated and blast-like myeloid cells
|
|
|
• enlarged granulocyte-macrophage progenitor (GMP) compartment
|
|
|
• increased circulating blast-like cells at 7 weeks after birth
• massive infiltration of differentiated and blast-like myeloid cells in the spleen
|
|
|
• with an increase in absolute myelomonocytic and blast-like cells 7 weeks after birth
|
growth/size/body
|
|
• with massive infiltration of differentiated and blast-like myeloid cells
|
hematopoietic system
|
N |
• colony assays of whole bone marrow cells show restored serial-replating capacity of cells and competitive transplantation experiments show restoration of the self-renewal defect seen in single conditional Asxl1 mutants
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tet2tm1.1Iaai mutation
(2 available);
any
Tet2 mutation
(778 available)
Tg(VAV1-cre)1Graf mutation
(1 available)
|
|
|
hematopoietic system
|
|
• increased myeloid progenitors in the spleen
|
|
|
• mice exhibit an increase in the GMP population (including monocyte and granulocyte progenitors) compared with wild-type mice
|
|
|
• at 20 weeks, progressive in the peripheral blood
|
|
|
• at 20 weeks, bone marrow and peripheral lymphoid tissue exhibit myeloid dysplasia (including blasts, promyelocytes, myelocytes, or metamyelocytes) unlike in wild-type mice
|
|
|
• hematopoietic progenitors exhibit increased serial replating capacity compared with control cells
|
neoplasm
|
|
• at 20 weeks, mice exhibit chronic myelomonocytic leukemia (CMML)-like phenotype unlike wild-type mice
|
immune system
|
|
• mice exhibit an increase in the GMP population (including monocyte and granulocyte progenitors) compared with wild-type mice
|
|
|
• at 20 weeks, progressive in the peripheral blood
|
|
|
• at 20 weeks, bone marrow and peripheral lymphoid tissue exhibit myeloid dysplasia (including blasts, promyelocytes, myelocytes, or metamyelocytes) unlike in wild-type mice
|
growth/size/body
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tet2tm1.1Iaai mutation
(2 available);
any
Tet2 mutation
(778 available)
Tg(VAV1-cre)1Graf mutation
(1 available)
|
|
|
hematopoietic system
|
|
• progressive in the peripheral blood
|
|
|
• in the peripheral blood
|
|
|
• hematopoietic progenitors exhibit increased serial replating capacity compared with control cells
|
immune system
|
|
• progressive in the peripheral blood
|
|
|
• in the peripheral blood
|
mortality/aging
|
|
• 40% of mice treated with polyinosinicpolycytidylic acid (pI:pC) at 4 weeks of life die by 50 weeks of age
|
hematopoietic system
|
|
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with pI:pC results in a myelodysplastic syndrome and mice exhibit lower white blood cell counts and hematocrit, presence of dysplastic erythroid precursors, dysplastic myloid cells, and increased extramedullary hematopoiesis
|
immune system
|
|
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with pI:pC results in a myelodysplastic syndrome and mice exhibit lower white blood cell counts and hematocrit, presence of dysplastic erythroid precursors, dysplastic myloid cells, and increased extramedullary hematopoiesis
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tet2tm1.1Iaai mutation
(2 available);
any
Tet2 mutation
(778 available)
Tg(Mx1-cre)1Cgn mutation
(7 available)
|
|
|
hematopoietic system
|
|
• block in erythroblast development resulting in an increase at development stage R2 and a decrease in R4 population in spleen at 45 weeks post-piPC
|
|
|
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with post-pIPC results in 100% donor chimerism by 24 weeks as compared to approximately 25% in wild-type
|
|
|
• increased percentage of granulocytes in peripheral blood and bone marrow at 45 weeks post-pIPC
|
|
|
• decrease in percentage of B cells in the spleen and bone marrow 45 weeks post-pIPC
|
|
|
• increase in long term repopulating hematopoietic stem cells (LT-HSC) in bone marrow 45 weeks post-piPC treatment
• increase in multi-potent progenitors (MPP) in bone marrow 12 weeks post-piPC treatment
• increase in short term repopulating hematopoietic stem cells (ST-HSC) in bone marrow 45 weeks post-piPC treatment
|
|
|
• in transplantation experiments, pIpC-treated hematopoietic stem cells exhibit increased self-renewal compared with control cells
|
immune system
|
|
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with post-pIPC results in 100% donor chimerism by 24 weeks as compared to approximately 25% in wild-type
|
|
|
• increased percentage of granulocytes in peripheral blood and bone marrow at 45 weeks post-pIPC
|
|
|
• decrease in percentage of B cells in the spleen and bone marrow 45 weeks post-pIPC
|
mortality/aging
|
|
• 17.7% of mice treated with polyinosinicpolycytidylic acid (pIpC) at 4 weeks of life die by 50 weeks of age
|
growth/size/body
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tet2tm1.1Iaai mutation
(2 available);
any
Tet2 mutation
(778 available)
Tg(EIIa-cre)C5379Lmgd mutation
(4 available)
|
|
|
normal phenotype
|
|
• mice are born with at the expected Mendelian ratio with normal growth and organ development
|
Analysis Tools